预约演示
更新于：2025-08-11
Methimazole
甲巯咪唑
更新于：2025-08-11
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1950-06-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C4H6N2S |
InChIKeyPMRYVIKBURPHAH-UHFFFAOYSA-N |
CAS号60-56-0 |
关联
54
项与 甲巯咪唑 相关的临床试验NCT06240455
A Double-blind, Placebo-controlled, Phase 2 Dose-range Study to Assess the Efficacy and Safety of WP1302 in Preventing Disease Relapse Following Methimazole Withdrawal in Subjects With Graves' Disease
ITMCTR2024000684
Correlation analysis of Xiakucao oral liquid combined with methimazole and rapid and stable recovery of thyroid function in patients with Graves' disease
ChiCTR2400092543
Clinical study on the effect of selenium combined with methimazole tablets on cognitive function in patients with initial hyperthyroidism
100 项与 甲巯咪唑 相关的临床结果
登录后查看更多信息
100 项与 甲巯咪唑 相关的转化医学
登录后查看更多信息
100 项与 甲巯咪唑 相关的专利（医药）
登录后查看更多信息
5,808
项与 甲巯咪唑 相关的文献（医药）2025-11-01COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
Effects of methimazole on the thyroid hormone system in Japanese medaka (Oryzias latipes) larvae
Article
作者: Yap, Chee Kong ; Horie, Yoshifumi
Thyroid hormones (THs) are essential for fish development, metabolism, and reproduction. Disruptions in TH balance caused by exposure to TH-disrupting chemicals (THDCs) can lead to serious physiological problems. While adverse outcome pathways (AOPs) for THDCs have been described in zebrafish and fathead minnows, similar pathways in Japanese medaka (Oryzias latipes) are still not well understood. In this study, we explored how methimazole (MMI), a thyroid peroxidase (TPO) inhibitor, affects the development of Japanese medaka, focusing on growth, swim bladder inflation, thyroid hormone (T4 and T3) levels, and gene expression patterns in this species. The results obtained indicated that MMI exposure suppressed T4 levels in a dose-dependent manner, but did not show any dose-dependent effects on the thyroid hormone-related genes expression levels or growth and the growth-related genes expression. Although the incidence of swim bladder inflation failure showed statistically significant differences, it was not dose-dependent; the inflation rate remained approximately 90 % across all exposure concentrations, suggesting no biologically meaningful effect. This observed disruption of T4 levels aligned with key events in established AOPs for THDCs. Furthermore, our findings provide valuable insights into the taxonomic domain of applicability for these AOPs.
2025-09-01TALANTA
Imidazole-triggered in situ fluorescence reaction system for quantitatively determination of dopamine from multiple sources
Article
作者: Yang, Hong ; Zhang, Lijie ; Zhu, Shanshan ; Liu, Jinhua ; Ma, Yifei
Highly selective and sensitive determination of dopamine (DA) from multiple sources remains a persistent and significant challenge. Here, we develop an imidazole-triggered in situ fluorescence reaction system for highly selective and sensitive determination of DA from various sources (human, horse, dog, rabbit, and mouse). The system operates by catalyzing the oxidation of DA with 1,5-Dihydroxynaphthalene (1,5-DHA) through a Lewis base formed by imidazole, leading to the rapid generation of yellow azamonardine fluorescent compounds (AFC). Notably, the system demonstrates minimal background noise and a high signal-to-noise ratio of up to 300-fold with a determination limit of 33.33 pM, making it 10-100 times more sensitive than conventional enzyme-linked immunosorbent assay (ELISA) methods. Moreover, selectivity tests reveal that our system can effectively distinguish between several common interfering substances, even at concentrations as low as 10 nM. The developed system shows promising results in detecting DA from diverse sources (humans, horses, dogs, rabbits, and mice), including urine samples from clinical patients, exhibiting good agreement with traditional ELISA kits. Therefore, the established in situ fluorescence reaction system holds great potential for the determination of DA-related disorders due to its impressive analytical capabilities.
2025-08-01Current Drug Safety
Methimazole-Induced Pancytopenia in a Patient with Graves' Disease: A Case Report and Literature Review
Review
作者: Quiroz-Aldave, Juan Eduardo ; Fabián, Katia Eugenia Rivera ; Concepcion-Urteaga, Luis Alberto ; Ildefonso-Najarro, Sofia Pilar ; Chavez, Karol Magdalena Moscol ; Paz-Ibarra, Jose ; Concepcion-Zavaleta, Marcio José
Introduction::
Methimazole is an antithyroid drug known to cause hematological toxicity,
including agranulocytosis and, very rarely, pancytopenia. We herein present a case of a patient
with Graves' Disease (GD) who developed methimazole-induced pancytopenia.
Case Report::
A 53-year-old Peruvian woman with GD, initially treated with methimazole 20 mg
BID, experienced odynophagia, fever, and malaise after 37 days of treatment. The initial diagnosis
was agranulocytosis, leading to the discontinuation of methimazole and initiation of antibiotics.
Due to persistent neutropenia, a Granulocyte Colony-stimulating Factor (G-CSF) was administered.
Eight days later, she developed pancytopenia and was managed with hematopoietic
agents and platelet transfusions. The patient recovered with normalization of the blood count,
eliminating the need for Bone Marrow (BM) examination. Radioiodine therapy was chosen as
the definitive treatment, resulting in hypothyroidism. Currently, the patient is thyroidal and hematologically
stable.
Conclusion::
Methimazole-induced pancytopenia is a rare and serious complication; however,
with appropriate treatment, complete recovery can be achieved.
100 项与 甲巯咪唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲状旁腺功能亢进症 | 中国 | 1986-01-01 | |
| 甲状腺功能亢进症 | 美国 | 1950-06-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性冠状动脉综合征 | 临床前 | 中国 | 2025-06-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Propylthiouracil (PTU) | 鑰鬱蓋鬱醖顧鬱鹹窪膚(廠鬱鹹願簾繭製構鏇夢) = 遞鹽憲顧壓遞憲憲構膚 顧窪繭醖餘壓壓範構鹹 (築衊夢膚鑰廠襯廠齋衊 ) | - | 2024-01-01 | ||
Methimazole (MMI) | 鑰鬱蓋鬱醖顧鬱鹹窪膚(廠鬱鹹願簾繭製構鏇夢) = 簾製築醖壓襯鑰膚壓觸 顧窪繭醖餘壓壓範構鹹 (築衊夢膚鑰廠襯廠齋衊 ) | ||||||
N/A | - | - | 憲鬱壓餘鏇構顧憲構夢(醖鏇窪繭膚鹹壓網鏇鹹) = 壓齋選憲鹽選範構觸糧 壓憲艱廠壓築選夢獵蓋 (蓋膚鏇鬱窪齋壓糧範積 ) 更多 | - | 2021-09-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用